Loading clinical trials...
Loading clinical trials...
Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients (Study DIAMUCO)
For some years, the investigators observe an increase of the arisen of diabetes in cystic fibrosis patients However, this diabetes may be reversible. The investigators speak about " Cystic fibrosis related diabetes.". The objective of this project, is to know better what facilitates the appearance and the reversibility of the diabetes, such as the genetic mutations, the respiratory state and the lung infections. Theses knowledges should allow to adapt the screening of diabetes, and its treatment, for the patients affected by cystic fibrosis.
Age
10 - 65 years
Sex
ALL
Healthy Volunteers
No
Service de Médecine Interne - Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Start Date
April 1, 2009
Primary Completion Date
October 1, 2014
Completion Date
October 1, 2014
Last Updated
September 4, 2025
230
ACTUAL participants
Prospective cohort with an annual follow-up
OTHER
Lead Sponsor
Hospices Civils de Lyon
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions